Status Flu A + B Test Manufactured by Princeton Bio Meditech Corporation Monmouth Junction, NJ 08852 USA. The BioSign Flu A + B test is an in vitro rapid qualitative test that detects influenza type A and type B nucleoprotein antigens directly from nasal swab, nasopharyngeal swab and nasal pharyngeal aspirate/wash specimens obtained from patients with signs and symptoms of respiratory infection. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. A negative test result is presumptive and it recommended that these results be confirmed by viral culture. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other management decisions. The test is intended for professional and laboratory use.
Publicado el 12 de septiembre de 2012 · Inicio del retiro: 9 de marzo de 2012
Resumen
FDA registra el retiro Z-2308-2012 de dispositivos médicos de Clase II, publicado el 12 de septiembre de 2012 e iniciado el 9 de marzo de 2012. Empresa responsable: Princeton Biomeditech Corp; Estado: Finalizado; Cantidad reportada: 90 kits (22 tests per kit); Lote: 510 k K083746 Catalog Number 36022 Lot numbers 441H11 90 kits (22 tests per kit). La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
There have been reports of dual positive (Flu A + Flu B positive) results being encountered.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Princeton Biomeditech Corp
- Distribuidor
- Nationwide Distribution-including the states of NJ, NY, and PA.
- Lote
- 510 k K083746 Catalog Number 36022 Lot numbers 441H11 90 kits (22 tests per kit)
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAOsom Ultra hCG Combo Test- IVD immunoassay for the qualitative detection of human chorionic gonadotropin (hCG)6 de noviembre de 2024
- FDAPoly stat Flu A & B Test Manufactured for Polymedco 510 Furnace Dock Road Cortlandt Manor, NY 10567 Tel12 de septiembre de 2012
- FDAOrasure QuickFlu Rapid A+B Test Manufactured for OraSure Technologies, Inc Bethlehem, PA 18015 USA. The12 de septiembre de 2012
- FDAZilver 518 Vascular Self Expanding Stent The Zilver Vascular Stent is intended for use as an adjunct to12 de septiembre de 2012
- FDAOPTETRAK LOGIC TIBIAL INSERT POSTERIOR STABILIZED***Match Component Colors 6 YELLOW, 11mm, Use with LOGIC12 de septiembre de 2012
- FDAsyngo(R) Lab Data Manager and syngo(R) Lab Process Manager, all versions. This device is classified as a data12 de septiembre de 2012
Preguntas sobre este retiro
¿Status Flu A + B Test Manufactured by Princeton Bio Meditech Corporation Monmouth Junction, NJ 08852 USA. The BioSign Flu A + B test is an in vitro rapid qualitative test that detects influenza type A and type B nucleoprotein antigens directly from nasal swab, nasopharyngeal swab and nasal pharyngeal aspirate/wash specimens obtained from patients with signs and symptoms of respiratory infection. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. A negative test result is presumptive and it recommended that these results be confirmed by viral culture. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other management decisions. The test is intended for professional and laboratory use. fue retirado del mercado?
Sí. FDA publicó el retiro Z-2308-2012 el 12 de septiembre de 2012. Peligro reportado: There have been reports of dual positive (Flu A + Flu B positive) results being encountered.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter